Background: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians. Results: Overall, the risk of SPMs in MM is low, multifactorial, and partially related to the length of patients' survival and MM intrinsic susceptibility. Studies suggest a significantly increased incidence of SPMs when lenalidomide is administered either following, or concurrently with, oral melphalan. Increased SPM incidence has also been reported with lenalidomide maintenance following high-dose melphalan, albeit to a lesser degree. In both cases, the risk of death from MM was significantly higher than the risk of death from SPMs, with lenalidomide possibly providing a survival benefit. No increase in SPM incidence was reported with lenalidomide plus dexamethasone (without melphalan), or with bortezomib plus oral melphalan, dexamethasone, or thalidomide. Conclusion: In general, the risk of SPMs should not alter the current therapeutic decision-making process in MM.
introduction
The potential for patients originally diagnosed with multiple myeloma (MM) to develop solid or hematologic second primary malignancies (SPMs) has long been recognized. Forty-five years ago, Dr Robert Kyle and co-workers described the subsequent development of acute myeloid leukemia (AML) in four patients who had received prolonged melphalan treatment for MM or systemic amyloidosis [1] . Nine years later, other researchers reported a greater-than-expected incidence of AML (14 cases, 3.8%) among 364 patients with MM treated with low-dose melphalan in combination with other alkylating agents [2] .
Subsequent Medical Research Council (MRC) studies strengthened the case for a link between prolonged alkylating agent exposure and SPM development in patients with MM, reporting 5-, 8-, and 10-year prevalences of myelodysplastic syndromes (MDS) or AML in MM patients treated with melphalan or (albeit less consistently) cyclophosphamide of 3%, 10%, and 20%, respectively [3] . More recently, detailed pathological analysis of myeloid neoplasms secondary to MM (mainly MDS or AML) has furnished support for the hypothesis that alkylating agents exert a mutagenic effect on the pathogenesis of hematologic SPMs, with evidence of complex cytogenetic abnormalities/ unbalanced aberrations of chromosomes 5/7 being particularly associated with melphalan/cyclophosphamide combinations [4] .
Over the past decade, the successive introduction of high-dose melphalan followed by autologous stem cell transplantation (ASCT) as standard initial therapy in younger patients, and of the first generations of 'novel' agents, such as the immunomodulatory drugs (IMiDs; thalidomide and lenalidomide) and the proteasome inhibitor bortezomib, has improved clinical outcomes and life expectancy in MM, with current expected median survival ranging from 5 to 8 years [5] [6] [7] [8] . However, increased life expectancy has rekindled concerns about the long-term risk of solid or hematologic SPMs [9] [10] [11] , particularly as the prognosis of many potential SPMs remains very poor in comparison with MM [12] [13] [14] [15] . A recent Swedish, population-based study of 26,627 patients diagnosed with MM between 1958 and 2011 confirmed a statistically significant 2.3-fold (95% confidence interval [CI] 2.1-2.5) increased mortality risk in patients with SPMs versus a control group of MM patients without SPMs [16] . The finding in randomized, phase III trials that lenalidomide maintenance therapy is associated with an increased risk of SPMs (7%-8%) versus placebo/observation (2%-3%), in both elderly [17] and transplant-eligible patients [18, 19] , has further added to these concerns [20] [21] [22] .
This paper aims to disseminate the latest knowledge of SPM risk factors in patients with MM, and provides practical recommendations and guidance to assist physicians in the management of such patients. In particular, a Panel composed of members of the International Myeloma Working Group has considered the following questions:
1. What is the 'true' risk of SPM development in patients with MM? 2. What are the possible host-and disease-related risk factors for SPMs in patients with MM? 3. Do older and novel therapies increase the risk of SPM development in MM?
The Panel's recommendations in relation to each of these questions are summarized in Table 1 what is the 'true' risk of SPM development in patients with MM? Table 2 summarizes major population-based, cancer registry studies that investigated SPM incidence in patients with MM. These studies generally found no overall increase in SPM risk among patients with MM, but did identify an augmented incidence of MDS, AML and, to a lesser degree, non-Hodgkin lymphoma (NHL). In contrast, significant heterogeneity in the risk of different solid SPM subtypes was observed (Table 2) .
It is difficult to draw firm conclusions about the 'true' risk of SPMs in MM, or to identify specific risk factors in a process that is likely multifactorial. First, the estimated overall risk reported is relatively small: the cumulative incidence of 1%-10% is comparable with the incidence of cancer per life-year in the general population [31] . Consequently, some reports-particularly of uncontrolled/retrospective and post-hoc studies-may underestimate SPMs, as they are not specifically tracked during followup. Conversely, over-reporting may occur if SPMs are expected to be found in specific arms or subgroups of trials, or when appropriate screening is used to prospectively detect early SPMs. In general, well-designed, registry-based, population studies, which include individual treatment and long follow-up, may be a more effective means of determining therapy-associated SPM risk than some randomized trials, which are limited by inclusion/exclusion criteria, lower power, and treatment crossover. • Well-designed, population-based studies suggest that the risk of SPMs in MM is low, and partially related to the lengthening survival of patients with MM.
• The risk of SPMs should be evaluated in individual patients, according to patient-, disease-, and treatment-related factors.
• Additional and systematic data gathering is needed to determine the incidence and types of SPMs in patients with MM currently treated both in clinical trials and in the real-world setting.
• Ongoing trial protocols should be amended to include enhanced monitoring and precise measurement of secondary cancers (including non-invasive neoplasms), and include SPMs as an 'a priori' well-defined endpoint. These measures should be integral to the design of any future prospective clinical trials.
• Prospective population-based studies gathering information on the baseline characteristics and treatment of individual patients should also report SPM data.
• SPM data collected in clinical trials and observational studies should include details of the time to development, clinical and biologic characteristics, prognosis, and natural history of SPMs observed.
• SPM incidence rates should be adjusted for person-years at risk (that is, rate per 100 person-years).
• Specific routine screening for SPMs, beyond that suggested for the general population, is not recommended. However, diagnostic measures that would aid the detection of suspected SPMs during daily clinical work-up should be considered, on a case-by-case basis, in long-term MM survivors. In particular, bone marrow examination with cytogenetic analyses (or FISH, if necessary) is recommended at baseline and in the event of unexplained blood count abnormalities in the real-life setting and in prospective observational and investigational studies.
• Every SPM case should be reviewed carefully to accurately assess the true impact of treatment on SPM development, and to prevent false inflation of reported SPM rates. What are the possible host-and disease-related risk factors for SPMs in patients with MM?
• The pathogenesis of SPMs in MM is likely to be multifactorial.
• Biologic samples from all MM patients included in clinical trials and, when possible, encountered in clinical practice, should be collected and stored for genetic analysis. Ideally, samples should yield DNA for genomic analysis or, better still, RNA for gene expression profiling. Collection of germline and tumor-related material, and re-banking of biologic samples during the course of the disease, are also recommended.
• Next-generation sequencing genomic studies designed to identify genetic profiles associated with increased SPM risk should be planned.
Do older and novel therapies increase the risk of SPM development in MM?
• Based on the available evidence, the potential risk of SPMs in MM should not generally alter the current therapeutic decision-making process.
• Data regarding the use of ASCT in MM are reassuring, and the Panel recommends that first-line therapeutic approaches in eligible MM patients should always include ASCT conditioned with high-dose intravenous melphalan.
• For the current approved indication of lenalidomide in the treatment of relapsed MM, the benefits of therapy clearly outweigh any risk of SPMs.
• Similarly, in front-line therapy without concurrent oral melphalan, regimens such as lenalidomide plus dexamethasone (or alternatives such as cyclophosphamide or alkylating-free combinations) remain safe and effective options that should be considered for patients with MM, instead of oral melphalan in combination with lenalidomide.
• In the maintenance setting, prolonged administration of lenalidomide where there is antecedent melphalan exposure should generally be avoided, with the important exception of high-dose melphalan used as a conditioning regimen for ASCT.
• All patients initiating lenalidomide maintenance should undergo a baseline bone marrow examination with cytogenetics to ensure that there is no overt evidence of dysplasia or concerning cytogenetic abnormalities. There should also be a low threshold for careful bone marrow analysis with karyotyping for patients with unexplained cytopenias that persist despite lenalidomide withdrawal.
• In cases where the overall survival benefit of maintenance therapy with lenalidomide is still not well established, the risks versus any possible benefits of treatment should be considered carefully.
• The potential increased risk of SPMs should be adequately addressed through appropriate discussion with the patient, bearing in mind current knowledge and providing updated and balanced information about treatment-associated pitfalls and benefits, specifically in terms of OS, thus enabling the patient to make informed decisions regarding treatment selection on this basis.
• Physicians should remain well informed about the latest data on the risk of SPMs in MM.
ASCT, autologous stem cell transplantation; FISH, fluorescence in situ hybridization; MM, multiple myeloma; OS, overall survival; SPM, secondary primary malignancies. n, number; NR, not reported; SIR, standardized incidence rate; SPM, secondary primary malignancy; ST, solid tumor; y, years.
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Pre-existing or concomitant neoplasms could represent additional confounding factors [32] [33] [34] [35] [36] . On the other hand, some studies suggest that SPM risk may be elevated as a 'natural' consequence of the increased survival achieved with current treatments, rather than as a direct result of the therapies themselves [9] [10] [11] .
Finally, a correct diagnosis of 'true' SPM is mandatory. An adhoc independent committee recently reviewed SPMs occurring in the UK MRC Myeloma XI study according to pre-determined criteria [37] . Of 88 reported cases, only 67 (76%) were confirmed as trial-related SPMs; the remaining cases were rejected because of: evidence that the second malignancy pre-existed prior to trial enrollment (57%); no evidence of malignancy found on further investigation (24%); reported non-malignant skin conditions (14%); and spontaneous resolution of cytopenias upon cessation of treatment (5%).
what are the possible host-and disease-related risk factors for SPMs in patients with MM?
SPM development is likely multicausal. In addition to specific treatments, possible risk factors may be classified as either hostor disease-related.
host-related risk factors
age and sex. Among potential host-related factors, older age and male sex have most commonly been associated with increased SPM incidence in patients with MM [18, 26, 38, 39] . Nevertheless, there are inconsistencies in the published data. Updated results from the Surveillance, Epidemiology, and End Results (SEER) program, for example, showed that the risk of AML development in patients with MM was increased 5-fold in those aged <65 years of age versus patients aged >75 years [27] . Meanwhile, women with MM were found to be at significantly increased risk of leukemia versus men [27] .
ethnicity. Several SEER-based analyses demonstrate an impact of ethnicity on the risk of SPM development in patients with MM [26, 40] . In an analysis of 2021 patients with MM and SPMs (diagnosed between 1973 and 2008), Hispanic whites had a significantly decreased observed/expected (O/E) risk of developing solid tumors, particularly lung/bronchus and prostate SPMs. Non-Hispanic whites showed an increased O/E risk of developing skin melanomas, NHL, and, more consistently, AML, while the risk of developing SPMs of the kidney/renal pelvis and AML was increased among African Americans. The O/E risk of AML as a SPM was also found to be significantly increased among Asian-Pacific Islanders [40] .
genetics. Genetic alterations and their interaction with environmental factors and/or therapy may contribute to familial and individual predisposition to MM and, possibly, to different SPMs [41] [42] [43] . Genotype studies have shown that germline mutations in the CDKN2A gene may predispose to both MM and other cancers [41] . Furthermore, the G/G phenotype of single nucleotide polymorphism (SNP) rs1617640 in the erythropoietin promoter gene has been found to be more common in individuals with MM who develop MDS versus those who do not [44] , thus confirming a potential role for susceptibility genes in the development of SPMs. Other genetic polymorphisms have been found to be associated with an increased risk of MM [45] , while conversely appearing to protect against specific solid SPMs [27, 46] . Genome-wide association studies and gene expression microarray analysis of patients with or without SPMs have identified several other candidate SNPs that are associated with acute leukemia after other neoplasms [47, 48] . Studies investigating baseline whole bone marrow gene-expression profiling, proteomic analyses, and SNPs are currently ongoing, with the aim of identifying patients who may have a marked propensity to develop SPMs [43] .
prior cancer. Studies have shown that prior or synchronously different malignancies (PSMs) are more common than SPMs in MM, occurring in 3%-24% of patients and thus representing a possible confounding factor when a diagnosis of SPM is suspected [33, 35, 36, [49] [50] [51] . While these tumors are often early stage or good-prognosis neoplasms, the largest group (up to 90%) of invasive PSMs comprises prostate, gastric, colorectal, and breast cancers, while fewer hematologic malignancies (10%-27%) have been reported.
Patients with PSMs frequently have a history of chemo-/radiotherapy, and/or hormone therapy, which confers a poor prognosis. In these patients, MM potentially occurs as a SPM. Interestingly, in a large Swedish study, MM patients with PSMs at diagnosis were not at increased risk of developing a subsequent SPM versus those without PSMs (odds ratio 1.19; 95% CI 0.97-1.46) [52] . These findings suggest that patients with MM and a PSM should not be denied the best available therapy because of fears of SPM development.
additional individual factors. Many additional socioeconomic, occupational, lifestyle, and environmental factors could potentially play a role in the development of SPMs. The potential involvement of such factors in the context of competing risks may be difficult to differentiate, especially if their real impact on the development of SPMs is small; consequently, no firm data have yet been produced in the setting of MM [10, 11, 53] .
disease-related risk factors
That MM by itself (independent of MM therapy) may be a risk factor for SPM development was first hypothesized nearly 40 years ago [54] . Since then, adverse cytogenetics, advanced disease stage, and some MM subtypes have been associated with increased SPM incidence. Interestingly, the risk of developing MDS/AML appears significantly increased in individuals with monoclonal gammopathy of undetermined significance (MGUS) versus the general population. For example, in a large, Swedish, population-based study, the risk of MDS/AML was increased 8-fold in the subset of 2293 patients with IgG or IgA MGUS versus age-and sex-matched individuals from the general population [24] . Risk levels were increased in patients with Mcomponent concentrations >1.5 g/dl versus those with lower levels, suggesting that the risk of MDS/AML development in MGUS patients with more extensive/advanced disease is similar to that in patients with symptomatic MM. As in MM, an excess risk of non-melanoma skin cancer was also seen in patients with MGUS.
A Mayo Clinic study systematically screened 17,315 individuals for the presence of MGUS [55] . Of the 605 patients found to have MGUS, seven were subsequently diagnosed with MDS, and review Annals of Oncology two with AML. Compared with non-MGUS controls, patients with MGUS had a 2.4-fold significantly increased risk of developing MDS; the risk of AML was slightly, but not significantly, increased, while no cases of acute lymphoblastic leukemia (ALL) were observed. In a subanalysis, MDS occurred in patients with all Ig isotypes (including IgM), while AML was observed only in patients with IgA/IgG. Such results were unchanged when 'early' MDS/AML patients, diagnosed within 1 year following diagnosis of MGUS, were excluded.
Despite differences in study design and number of MGUS patients included, the Swedish and Mayo Clinic findings both suggest a possible intrinsic causal role for plasma cell disorders, and a consequent inherent increased risk of MDS/AML that is independent of MM therapy. Recently, however, International Staging System stage and history of smoldering myeloma or MGUS were found to have no impact on SPM occurrence in a large, US disease registry study [29] . Interestingly, plasma cell cytogenetic abnormalities were linked with an increased SPM incidence in symptomatic MM (hazard ratio [HR] ¼ 1.64, P < 0.05), when modeled from study enrollment in the Total Therapy (TT) trials [56] . Furthermore, three of the patients who ultimately developed MDS/AML in the lenalidomide arm in the MM-015 trial were among 11 patients with plasma cell complex cytogenetics at baseline [57] . In contrast, predominantly favorable cytogenetics have been reported in patients who develop SPMs, suggesting that less aggressive MM and long disease latency may favor the manifestation of additional malignancies [30] .
Tumor-induced immunodeficiency, deregulated release of cytokines, chronic inflammation, and common tumor cell precursors may also play an important role in increasing the susceptibility of MM patients to SPM development [58] . Immunologic defects may include quantitative and functional abnormalities in T-cell and B-cell compartments, natural killer and dendritic cell populations, and neutrophils, as well as abnormal cytokine production, modified membrane antigen/receptor expression, and impaired phagocytosis. Multiple relapses and salvage therapies, using older and newer drugs in sequence, may also result in cumulative immunosuppression/dysfunction, further compromising immune surveillance against tumor cells. This could play a particularly significant role in increasing the risk of various skin cancers, including melanoma. Modified sex hormone levels could explain the decreased risk of some hormone-related solid SPMs, including breast and prostate cancer, observed in MM. Less frequent screening after MM diagnosis, however, is another possible explanation for the reported reduced risk of these solid SPMs [27] .
do older and novel therapies increase SPM risk in MM?
Early studies identified that prolonged exposure to melphalan increases the risk of hematologic SPM development (in particular, MDS/AML) in patients with MM, likely as a result of a direct mutagenic effect inducing DNA damage [1] [2] [3] [4] . The MM treatment paradigm has evolved significantly over the past few years, and numerous studies have continued to investigate treatmentrelated risk factors for SPMs. The characteristics and findings of the key retrospective studies and prospective first-line phase III randomized trials that have gathered information on the impact of various anti-myeloma treatments on SPM incidence in patients with MM are summarized in Tables 3 and 4, respectively. radiotherapy Radiation dose and extended fields are supposed, but not well proven, factors favoring SPM development in patients with MM. Indeed, several solid SPMs have been described in MM patients following combination chemo-radiotherapy [10, 24, 49, 56] . However, compared with other malignancies in which locoregional radiation treatments may induce SPMs in surrounding tissues (including bone marrow), information about the exact role of radiotherapy and risk of SPMs in MM is currently limited. Recent US Connect MM registry data did not support a relationship between radiotherapy and SPM incidence [29] ; this could be due to the lower radiotherapy dose usually administered to patients with MM.
ASCT
Data suggest that secondary MDS/AML risk is increased following ASCT in patients with lymphoma (14.5% cumulative incidence up to 15 years) [72] . This risk is increased further by older age, male sex, obesity, and pre-transplant treatment with alkylating agents [13, 38] . In contrast to lymphoma patients, however, studies have found no significant increase in SPM incidence following ASCT in patients with MM [24, 27, 38, 73] . In particular, a recent retrospective study in the USA found a similar incidence of new cancers in a large auto-transplantation cohort to that in age-, race-, and gender-adjusted comparison subjects [38] .
SPM rates in patients with MM post-ASCT may be attributable to 'conventional', alkylating agent-incorporating therapy prior to transplantation, rather than to the myeloablative therapy itself. For example, while investigating the possible role of highdose melphalan in augmenting the risk of secondary MDS/AML in MM patients, Govindarajan et al. [61] observed seven MDS cases in 117 patients who had received extended courses of chemotherapy prior to tandem ASCT, whereas no cases were observed among 71 patients who received limited chemotherapy before ASCT [61] . The authors concluded that preceding treatments, and not conditioning with high-dose melphalan, were the likely cause of MDS post-ASCT.
The low risk of SPM development after ASCT in MM versus lymphoma patients may be partially explained by the earlier use of transplants in MM, the attention paid to avoiding pretransplant stem-cell-damaging agents, and the cessation of total body irradiation during conditioning [74] .
novel agents
IMiDs: thalidomide and lenalidomide. Initial population studies found no relationship between SPM incidence in MM and treatment with novel agents, including thalidomide and lenalidomide [24, 27, 60] . However, these studies were limited by a short follow-up period, lack of focus on SPMs, and the non-uniform use of novel agents during their first few years of availability. Several major studies have since indicated that lenalidomide may increase SPM risk, particularly in the maintenance setting [75] . These studies include three large, phase III, randomized trials (IFM 2005-002, CALGB 100104, MM-015), all of which reported a significantly increased incidence of SPMs in newly diagnosed patients with MM who received lenalidomide maintenance versus similar patients who did not receive lenalidomide maintenance after either ASCT [18, 19, 76] or induction therapy [17, 77] . A recent update to CALGB 100104 confirmed that lenalidomide maintenance post-ASCT is associated with an increased risk of SPMs versus placebo [78] ; however, a post-hoc survey of this study raised the possibility that the entire patient population may have had an inherent risk for other malignancies, due, at least in part, to risk factors such as age, prior tumors, prior therapies, and family history [50] . Interestingly, secondary ALL after lenalidomide treatment has been reported only rarely [18, 79] .
A 2014 meta-analysis of seven randomized, controlled, phase III clinical trials that included lenalidomide as first-line therapy reported increased hematologic SPM incidence in newly diagnosed MM patients: 32/2620 (1.2%) versus 3/598 (0.5%) in patients treated (þL) or not treated (ÀL) with lenalidomide [39] . The cumulative incidence at 5 years was 3.1% (95% CI 1.9-4.3%) in the þL group versus 1.4% (95% CI 0.0-3.6%) in the ÀL group. In þL patients, SPM incidence increased linearly over time, and was significantly higher than in ÀL patients (HR ¼ 3.8, 95% CI 1.15-12.62, P ¼ 0.029). Co-exposure to lenalidomide and oral melphalan appeared to be the main driver of increased hematologic SPM risk (5-year cumulative incidence 3.9%), while lenalidomide plus cyclophosphamide (not estimable), lenalidomide alone (1.3%), and melphalan alone (1.4%) had no impact. The hematologic SPM risk associated with the combination of oral melphalan plus lenalidomide was also significantly increased (HR ¼ 4.86, 95% CI 2.79-8.46, P <0.0001) versus high-dose intravenous melphalan and lenalidomide (HR ¼ 2.21, 95% CI 0.49-10.02, P ¼ 0.304). The distribution of solid SPMs was similar in the þL and ÀL groups, with the exception of urinary tract tumors, which were more common in the þL group, probably as a consequence of the renal excretion of lenalidomide. Importantly, the risk of SPM-related mortality in the þL group (2.4%) was significantly lower than the risk of death due to either MM (26.5%) or treatment-related adverse events (9.8%) [39] .
A still-unpublished meta-analysis of three randomized trials including a total of 1188 patients with newly diagnosed MM who received lenalidomide maintenance, placebo, or no maintenance following ASCT [18, 19, 65] , was presented at the June 2016 Annual Meeting of the American Society of Clinical Oncology [80] . Lenalidomide maintenance was associated with an increased HR of 2.03 (95% CI 1.14-3.61, P ¼ 0.015) for hematologic SPMs and 1.71 (95% CI 1.04-2.79, P ¼ 0.032) for solid tumors. However, the survival benefit of lenalidomide maintenance (a 26% reduction in mortality risk, with an estimated 2.5-year increase in median survival) largely outweighed the increased risk of SPM development across all subgroups and response categories.
Several other studies have also suggested that, in patients with either newly diagnosed or relapsed/refractory MM, SPM risk may be increased with lenalidomide plus oral melphalan, but not with lenalidomide plus cyclophosphamide [81, 82] or dexamethasone [36, [64] [65] [66] [83] [84] [85] [86] . As no increase in SPM incidence has been reported with lenalidomide in combination with dexamethasone, even on prolonged administration [66, [84] [85] [86] , a possible 'protective' effect of this drug might be considered. Different melphalan dose [67] and/or lenalidomide dosing schedules (3 weeks on, 1 week off versus continued treatment) could explain the lack of increased SPM incidence in some studies of lenalidomide maintenance therapy. The actions of lenalidomide are complex, and the mechanism(s) by which it might favor SPM development remain undefined. Lenalidomide's immunosuppressive activity, and its effects on the tumor microenvironment, may favor the escape/ growth of abnormal clones that could result in SPM development. Alternatively, treatment-related MDS/AML might be caused by a possible damaging stem-cell effect of lenalidomide. Cereblon, a molecular target for the anti-MM activity of lenalidomide, is a component of the E3 ubiquitin-ligase complex that is essential for nucleotide excision repair [87] . Inhibition of cereblon/DDB1 complex by lenalidomide impairs repair mechanisms after melphalan-induced DNA damage, and could therefore facilitate the development of SPMs [87] .
The TT2 trial showed a trend for increased solid SPM risk from the initiation of maintenance therapy in the TT plus thalidomide maintenance versus the TT without thalidomide arm [56] . This suggests an IMiD class effect, rather than a lenalidomide-specific effect, associated with alkylator exposure. However, the absence of a randomized comparison and the number and variety of drugs used in the TT trials make it difficult to determine whether the thalidomide-associated increased SPM risk in TT2 is of similar magnitude to that seen with lenalidomide.
bortezomib. Studies conducted to date indicate that bortezomib is associated with a low risk of SPM development. For example, after 54 months' follow-up, SPM incidence in elderly patients with MM who were treated with VMPT-VT (a fourdrug combination comprising bortezomib, melphalan, prednisone, and thalidomide, followed by maintenance treatment with bortezomib plus thalidomide) was 0.9% versus 1.5% in similar patients treated with VMP (bortezomib, melphalan, and prednisone) [69] . In the phase III VISTA trial in patients with previously untreated MM, incidences of hematologic and solid tumor SPMs after 60.1 months' follow-up did not differ significantly between VMP-treated patients (1% and 5%, respectively) versus those treated with melphalan plus prednisone (1% and 3%, respectively), and were consistent with background rates [70] .
Mature data on the incidence of SPMs were recently available for 299 patients enrolled in the phase III, multicenter, GIMEMA 26866138-MMY-3006 clinical trial that compared bortezomib, thalidomide, and dexamethasone (VTD) versus thalidomide plus dexamethasone (TD) as induction before, and consolidation after, a double ASCT [71] . The proportion of patients who developed SPMs was lower in the VTD (5%) than in the TD arm (11%, P ¼ 0.068). Among those patients who developed SPMs, solid (75% versus 71%) and hematologic (25% versus 29%) SPM rates were similar in the two arms. In the overall population, SPM incidence was significantly reduced at 6 years among patients randomized to VTD versus TD (6% versus 13%; P ¼ 0.037). These data suggest that bortezomib is associated with a low risk of SPM development, and that this particular drug may even decrease the risk of SPMs due to thalidomide when used in combination. A large, single-institution, registry analysis of host-, myeloma-, and treatment-specific risks for SPMs in 744 consecutive MM patients recently confirmed that cumulative incidence rates for SPMs were decreased in bortezomib-treated patients [30] . other novel agents. Consolidated data examining the SPM risk associated with the novel proteasome inhibitors carfilzomib and ixazomib, the third-generation IMiD pomalidomide, the histone-deacetylase inhibitor panobinostat, and the monoclonal antibodies elotuzumab (anti-SLAMF7) and daratumumab (anti-CD38) are not yet available. However, none of the studies published or presented to date reported an increased SPM risk in patients treated with these drugs [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] . In particular, when specifically investigated in relapsed/refractory MM treated in randomized trials including a control arm with lenalidomide plus dexamethasone, the incidence of SPMs was: 2.8% with a combination of carfilzomib, lenalidomide, and dexamethasone (versus 3.3% in the control arm) [91] ; 5% with ixazomib, lenalidomide, and dexamethasone (versus 4% in the control arm) [92] ; 2.8% with daratumumab, lenalidomide, and dexamethasone (versus 3.6% in the control arm) [101] ; and 6.9% with elotuzumab plus lenalidomide, and dexamethasone (versus 4.1% in the control arm) [97] . In the latter study, SPM incidence after adjustment for exposure to study therapy was 3.5% versus 2.8% per 100 person-years in the elotuzumab versus the control arm.
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